: Arterial Network
2020 is undoubtedly a breakthrough year for the medical AI industry. In just 7 months, artificial intelligence imaging software has successively won the three types of medical device certificates given by the State Drug Administration. Ande Medical Intelligence is one of them. In June, this AI company received the first domestic AI "image-aided diagnosis" NMPA Class III certificate.
Immediately after August, As a member of the consortium, Ande Medical Intelligence won the bid for the only national-level medical artificial intelligence public platform project of the Ministry of Industry and Information Technology of the People's Republic of China-"A Public Service Platform for Artificial Intelligence Aided Diagnosis for the Medical and Health Industry", with a bid amount of 168 million yuan . The consortium units that jointly form this national project are: Huawei, China Mobile, PLA General Hospital (301 Hospital), Tiantan Hospital, Peking University First Hospital, Tongren Hospital, Peking University Cancer Hospital, Zhengzhou University First Affiliated Hospital, China Institute of Food and Drug test. According to insiders in the industry, “the top-tier lineup of powerful alliances demonstrates the country’s determination to build artificial intelligence in healthcare and serve the people.” Why did
choose the national medical AI-assisted diagnosis platform?
In fact, it is not difficult to find the logic behind each step after counting the development of Ande Medical Intelligence.
In December 2019, according to the "Notice of the General Office of the Ministry of Industry and Information Technology on Printing and Distributing the List of Listed Units for the Key Tasks of the New Generation of Artificial Intelligence Industry Innovation" (Gongxindian Kehan [2019] No. 284), Ande Medical Intelligence as the unveiling The unit carried out technical research on the "Medical Imaging Aided Diagnosis System" project. It is reported that Ande Medical Intelligence ranked first in this list.
During the 2020 COVID-19 pandemic, Ande Medical Intelligence, Tiantan Hospital, and General Hospital of the People’s Liberation Army have been struggling for 16 consecutive days after receiving the special task of "Aided Diagnosis of New Coronavirus Pneumonia CT Image Artificial Intelligence" by the Ministry of Industry and Information Technology (Gongke Han [2020] No. 66) Day and night, the BioMind “new crown” pneumonia CT image AI qualitative auxiliary diagnosis system was quickly developed. Because of its outstanding contributions to the prevention and control of the epidemic, Ande Medical Intelligence was awarded the "2020 New Crown Epidemic Prevention and Control Ministry of Industry and Information Technology Commendation Unit".
In July of this year, in the national "Pneumonia AI Image Assisted Diagnosis Product Evaluation" organized by the Ministry of Industry and Information Technology, Ande Medical Intelligence stood out among the 17 medical AI companies participating in the evaluation and was commended.
At the same time, after fierce competition, As a member unit of the consortium, Ande Medical Intelligence successfully won the bid for the only national medical artificial intelligence platform project of the Ministry of Industry and Information Technology-"A Public Service Platform for Artificial Intelligence Aided Diagnosis in the Medical and Health Industry". The consortium units participating in this national-level project include: Huawei, China Mobile, PLA General Hospital (301 Hospital), Tiantan Hospital, Peking University First Hospital, Tongren Hospital, Peking University Cancer Hospital, Zhengzhou University First Affiliated Hospital, China Institute of Food and Drug test. The
winning document stated that: (the project) takes the lead and participates in the hospital, and ranks among the world's leading medical institutions in such disciplines as the heart and lungs, brain, eye, blood vessel, orthopedics, and oncology. Ande Medical Technology Co., Ltd., Huawei , China Mobile are benchmark companies in the fields of medical artificial intelligence, cloud computing, chip design, and network communications. "Z1z
In this national project, Ande Medical Intelligence needs to play multiple roles in AI, big data and other fields: Based on multi-modal biomedical data, and Huawei Technologies Co., Ltd. jointly develop a deep learning framework and a new generation of neural networks. Algorithm, lead the construction of platform network information security system, lead the research and development of medical artificial intelligence application products, participate in the formulation of artificial intelligence medical and health national/industry standards (draft), and participate in the establishment of the clinical performance evaluation index system of artificial intelligence medical and health products.
, To promote the fair accessibility of national medical resources
It is not difficult to see that in this national project, the country is committed to promoting the fairness and accessibility of China's medical resources through artificial intelligence technology, thereby improving the health and well-being of the people.
Consortium The member units not only "snap the top" in the field of subdivided diseases, but also have a clear division of labor: The PLA General Hospital takes the lead in completing the construction of artificial intelligence screening and auxiliary diagnosis systems for the heart, blood vessels, lungs, and breasts; Tiantan Hospital takes the lead in brain tumors and brain Vascular diseases, stroke and other diseases; Peking University First Hospital takes the lead in kidney and prostate fields; Peking University Cancer Hospital takes the lead in the field of gastrointestinal tumors; Tongren Hospital takes the lead in the field of visceral diseases such as eye, ear, nose and throat; The First Affiliated Hospital of Zhengda University takes the lead in blood and orthopedics , Uterus and other diseases.
Ande Medical Intelligence is responsible for the research and development of artificial intelligence applications in the above diseases. In fact, Ande Medical Intelligence has already worked hard around "breadth + depth", dedicated to truly solving clinical needs, and developing medical AI applications that are suitable for various clinical medical scenarios, practically solve doctors’ problems, and have real clinical value. .
In terms of in-depth research and development, taking neurological diseases as an example, Ande Medical Intelligence takes the lead in the world to realize CT/MRI imaging artificial intelligence-assisted diagnosis of neurological diseases, including more than 60 diseases including brain tumors, small vessel diseases, and strokes. , The diagnostic accuracy rate exceeds 90%, and the diagnostic accuracy rate of some diseases exceeds 96%. In October of this year, at the International Conference on Global Cerebrovascular Disease-the 6th Annual Conference of the Chinese Stroke Society and the Tiantan International Cerebrovascular Disease Conference, Ande Medical Intelligence released another major breakthrough-"BioMind Intracranial Aneurysm Artificial Intelligence The “assisted diagnosis system” has better performance indicators such as specificity and accuracy than similar top international products.
In terms of breadth, in fact, Ande Medical Intelligence has already realized the application of covering multiple parts of the body and multiple diseases in the field of medical AI-assisted diagnosis. The series of applications include: neurological diseases imaging AI (brain tumor, cerebral small vessel disease, stroke, etc.), lung diseases (including pneumonia classification, tuberculosis, lung cancer and other auxiliary diagnosis), cardiovascular and cerebrovascular diseases CTA/CTP/MRP, heart diseases MR, breast disease MRI, etc., have become AI applications that cover multiple parts of the body, such as the head, neck, heart, blood vessels, and breast, to accurately assist in the diagnosis of multiple diseases.
At the same time, Ande Medical Intelligence has also developed the BioMind cerebrovascular disease clinical diagnosis and treatment auxiliary decision-making system, from the diagnosis, treatment, and prognosis of the whole process of auxiliary decision-making, to help doctors realize that from the patient’s admission to discharge, it can be in the diagnosis and treatment guidelines and Based on the real-time update of patient data, clinical decisions can be made scientifically and reasonably.
Therefore, Ande Medical Intelligence is based on the dimensions of "disease type + disease course", and implements the application of auxiliary diagnosis and treatment decision-making, and promotes the establishment of the national medical AI auxiliary diagnosis system to improve the basic medical service by meeting more primary medical needs. Level, so that more high-quality medical resources will sink to the grassroots level to help graded diagnosis and treatment and healthy China. The three types of
are coming one after another. What is the difference between "imaging-aided diagnosis"?
In June this year, Ande Medical Intelligence obtained the NMPA Class III certificate. This is the first medical AI software approved by the National Food and Drug Administration to be named "image-assisted diagnosis".
It is the BioMind "Tianyizhi" intracranial tumor magnetic resonance imaging-assisted diagnosis software under Ander Yizhi's BioMind that has been approved for the first three types of AI "image-aided diagnosis". Talking about how to truly realize the "assisted diagnosis" function, Wu Zhenzhou, chief technology officer of Ande Medical Intelligence, said that the software does not stop at the early screening of diseases, but can make further accurate diagnosis of diseases. For example, it can accurately classify and diagnose brain tumors (such as meningioma, acoustic neuroma, medulloblastoma, glioma, etc.), and automatically generate a structured report to help doctors quickly diagnose, improve work efficiency, and improve diagnosis.
's solid product strength has helped Ande Yizhi successfully open the international market. In 2018, Ande Yizhi obtained product certifications from more than a dozen countries including the European Union CE, Singapore and other countries. The products are sold to Germany, Poland, Luxembourg, Singapore, etc. Many countries and regions.
This may give us some industry inspiration. In recent years, as national policies have become more active towards AI medical products, the industrialization prospects of medical AI have gradually become clear. "Sellers" can finally enter the market for legal sales. However, whether "buyers" are willing to pay the bill, the key is to look at "sellers." Whether the products provided really meet the demand.
In other words, for medical AI products, obtaining the three types of certificates is only the first step in commercialization, and it is the key to truly have clinical value.
With the continuous advancement of the approval of the three types of medical AI certificates, it is not difficult to imagine that in the future, people will continue to get market-oriented admission tickets. But who can go to the end, the market will tell us the answer based on value.
